Optimistic Buy Rating for ANI Pharmaceuticals Despite Clinical Trial Challenges

H.C. Wainwright analyst Brandon Folkes has maintained their bullish stance on ANIP stock, giving a Buy rating on July 18.

Brandon Folkes has given his Buy rating due to a combination of factors that suggest potential growth for ANI Pharmaceuticals. Despite the NEW DAY clinical trial not meeting its primary endpoint, the results still indicate a numerical reduction in supplemental aflibercept injections for Iluvien, which is promising for its use in treating diabetic macular edema (DME). The trial results, although not statistically significant, support the potential for increased uptake among the 50,000 patients who could benefit from Iluvien, beyond the current market expectations.
Furthermore, the secondary endpoints of the trial showed positive outcomes, such as a longer mean time before needing supplemental injections in the Iluvien arm compared to the aflibercept arm. This, along with the consistent adverse event profile, suggests that Iluvien remains a viable option for patients not responding to anti-VEGF treatments. The financial guidance for Iluvien and Yutiq revenue in 2025 also indicates a positive outlook, potentially driving ANIP’s stock value higher. These factors collectively contribute to Folkes’s optimistic Buy rating for the stock.

In another report released on July 18, Leerink Partners also reiterated a Buy rating on the stock with a $85.00 price target.